Can I Get a Michigan Medical Marijuana Card for Multiple Sclerosis (MS)?

Yes — multiple sclerosis (ms) qualifies under the Michigan Medical Marihuana Program

Multiple sclerosis is a qualifying condition under the Michigan Medical Marihuana Program (MMMA). The "severe and persistent muscle spasms" caused by MS are explicitly listed in Michigan law as a qualifying condition, and MS itself is a recognized qualifying diagnosis. Cannabis is one of the few therapies with strong international regulatory support specifically for MS-related symptoms — most notably for spasticity, which can be debilitating and is often inadequately controlled by first-line antispastic medications.

Common symptoms

• Muscle spasticity and stiffness
• Neuropathic pain
• Bladder dysfunction
• Fatigue
• Sleep disturbance
• Tremors
• Cognitive symptoms

How medical cannabis may help

THC and CBD have well-documented effects on muscle spasticity. Sativex (nabiximols), an oral cannabis-derived oromucosal spray containing equal parts THC and CBD, is approved for MS-related spasticity in more than 25 countries including the United Kingdom, Canada, Germany, Italy, and Spain (it is not FDA-approved in the United States, though it has been studied in U.S. clinical trials). Beyond spasticity, cannabinoids address several other MS-related symptoms simultaneously: neuropathic pain (a common feature of MS), sleep disturbance, bladder dysfunction in some patients, and the chronic fatigue that accompanies the disease. Many MS patients value the multi-symptom benefit of medical cannabis — addressing several MS-related issues with one therapy rather than stacking multiple medications.

Evidence base

Multiple Phase III randomized controlled trials of nabiximols (Collin et al. 2007 and 2010, Novotna et al. 2011) have demonstrated meaningful reductions in spasticity scores, patient-reported symptom severity, and sleep disturbance in MS patients who had inadequate response to standard antispastic therapy. Long-term observational studies in countries where Sativex is approved have shown sustained benefit and acceptable safety profile. The 2017 NASEM report concluded there is "substantial evidence" that oral cannabinoids are effective for MS-related spasticity — one of the strongest evidence categories the report assigned.

Michigan certification requirements

Documentation of your MS diagnosis from a neurologist is helpful — recent neurology notes, MRI reports showing demyelinating lesions, or a list of disease-modifying therapies you have used. Coordination with your treating neurologist about adding medical cannabis as adjunct therapy is strongly recommended, both for safety and for continuity of care.